Medication info
Bilsus Tablets 50mg (Vildagliptin)

Bilsus Tablets 50mg (Vildagliptin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tablet
Manufacturer / importer
Geonil Biofarm Co., Ltd.
Appearance
White to light yellow round tablets
Packaging
28 tablets/box [14 tablets/PTP(x2)]
Approval status
Active

MFDS item code 202200077 · Approved 2022.01.04 · Insurance code 073000900

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine may be administered as monotherapy or, in patients with no previous experience of antidiabetic drug therapy, in combination with metformin at a dose of 50mg once daily in the morning or 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or thiazolidinedione monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, once-daily administration of vildagliptin 100mg was not more effective than administration of 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is added (as triple therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is added is 100mg per day, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses greater than 100mg per day are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia. If you miss a dose of this medicine, take it as soon as you remember and take the next dose at your usual time. If you remember when it is nearly time for your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is required. Moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended.

Ingredients

Manufacturer
Geonil Biofarm Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication assists in improving blood sugar control for patients with type 2 diabetes in conjunction with dietary and exercise regimens. It can be initiated as monotherapy, and may be used alone or in combination with metformin in patients without previous treatment experience. It can also be used in combination with medications like sulfonylureas, metformin, and thiazolidinediones when blood sugar control is inadequate with monotherapy. Additionally, it can be added to treatment regimens with sulfonylureas, metformin, or insulin when adequate blood sugar control is difficult to achieve. In summary, this medication effectively enhances blood sugar control across various treatment stages for type 2 diabetes.

How to take

Adult dose

This medicine may be administered as monotherapy or, in patients with no previous experience of antidiabetic drug therapy, in combination with metformin at a dose of 50mg once daily in the morning or 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or thiazolidinedione monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, once-daily administration of vildagliptin 100mg was not more effective than administration of 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is added (as triple therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is added is 100mg per day, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses greater than 100mg per day are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia. If you miss a dose of this medicine, take it as soon as you remember and take the next dose at your usual time. If you remember when it is nearly time for your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is required. Moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended.

Precautions

This medication should not be used in certain patients. Patients with allergies to this drug's active ingredient or other components, patients with type 1 diabetes, and patients with diabetic ketoacidosis should not be administered this drug. Furthermore, patients with lactose intolerance or genetic lactose-related conditions should not take this medication. While taking this medication, it is important to regularly undergo liver function tests, as liver function abnormalities may rarely occur before and during treatment. If there is a significant increase in liver enzymes or symptoms like jaundice appear, the medication should be discontinued immediately. This medication may cause hypoglycemia, particularly when taken with sulfonylureas, raising the risk of hypoglycemia. Immediate action should be taken if hypoglycemic symptoms appear, and dosage adjustments should be discussed with a physician if necessary. This medication is not recommended for pregnant or breastfeeding women. It is safest to avoid taking it during pregnancy or breastfeeding. It can be used in elderly patients without separate dosage adjustments, but its safety and efficacy have not been established in children and adolescents under 18 years of age, hence it is not recommended for use in this population. Dizziness may occur during treatment, so caution should be exercised when driving or operating machinery. Severe joint pain or skin symptoms like blisters or ulcers should be reported to a doctor immediately for treatment. If symptoms of acute pancreatitis are suspected, the use of this medication should be stopped immediately, and patients with a history of pancreatitis should use it cautiously. In the case of overdose, as there is no specific antidote, appropriate treatment and supportive therapy according to symptoms may be necessary. This medication should be kept out of the reach of children and should not be transferred to other containers.

Side effects

  • Hepatitis
  • impaired liver function
  • angioedema
  • tremor
  • headache
  • dizziness
  • fatigue
  • nausea
  • hypoglycemia
  • nasopharyngitis
Show 90 more
  • asthenia
  • constipation
  • weight gain
  • peripheral edema
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood sugar
  • hyperhidrosis
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe and disabling joint pain
  • cutaneous vasculitis
  • cholecystitis
  • acute myocardial infarction
  • nodular arrhythmia
  • acute cholecystitis
  • pneumothorax
  • cholelithiasis
  • femoral fracture
  • peripheral artery occlusive disease
  • supraventricular tachycardia
  • congestive heart failure
  • gastric ulcer
  • gastric cancer
  • increased INR
  • appendicitis
  • pulmonary edema
  • vertigo
  • chest discomfort
  • dyspnea
  • cough
  • dyspepsia
  • drowsiness
  • pruritus
  • dry mouth
  • vomiting
  • insomnia
  • renal impairment
  • lip blisters
  • hunger
  • sensory loss
  • spinal canal stenosis
  • abdominal pain
  • gastroenteritis
  • gastritis
  • gastric ulcer
  • belching
  • appendicitis
  • fatty liver
  • hyperkalemia
  • hypertriglyceridemia
  • heart failure
  • cardiomegaly
  • angina pectoris
  • cardiac arrest
  • renal cyst
  • lung cancer
  • leg pain
  • increased C-reactive protein
  • myalgia
  • paresthesia
  • fever
  • edema
  • hand and foot edema
  • joint pain
  • upper respiratory infection
  • vesicular pemphigoid
  • dizziness
  • headache
  • constipation
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • peripheral edema
  • headache
  • nausea
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood sugar
  • dizziness
  • tremor
  • asthenia
  • hypoglycemia
  • hyperhidrosis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container and kept in a cool place below 30 degrees Celsius, protected from moisture. Storing it this way will help maintain the drug's efficacy for a longer period.

Appearance and packaging

Appearance

White to light yellow round tablets

Package unit

28 tablets/box [14 tablets/PTP(x2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.